Literature DB >> 7822152

Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina.

K U Löffler1, D P Edward, M O Tso.   

Abstract

PURPOSE: Increased immunoreactivity (IR) of beta-amyloid and the amyloid-associated proteins tau and amyloid precursor protein (APP) in the brain have been linked to the pathogenesis of neurodegenerative disorders such as Alzheimer's disease. However, the expression of these proteins has not been investigated in the normal or diseased human retina.
METHODS: Using immunohistochemical techniques, we examined the distribution and age-related changes of anti-tau-1, anti-tau-2, anti-APP, and anti-beta-amyloid IR in the human retina at various ages (n = 24), in retinitis pigmentosa (RP, n = 6), and in age-related macular degeneration (ARMD, n = 10).
RESULTS: Tau-1 immunoreactivity was intense in the inner retinal layers and did not change with age or in RP. Eyes with ARMD showed less intense staining but exhibited a similar distribution. Tau-2 IR was faint and did not change with age but was mildly increased in the retinal pigment epithelium (RPE) of eyes with RP and in the retina of eyes with ARMD. APP IR was most prominent in the ganglion cell and nerve fiber layer, and it appeared to increase in ganglion cells of older persons and in RPE cells of eyes with RP and ARMD. Beta-amyloid IR was only detected focally in sub-RPE deposits in eyes from older persons.
CONCLUSIONS: The proteins investigated in this study are present in the human retina. The staining pattern of tau is different from the brain, but it shows no age-related changes. The increased immunoreactivity of APP in retinal ganglion cells of older eyes and in RPE cells of eyes with RP and ARMD, as well as the patchy staining of beta-amyloid within sub-RPE deposits, might indicate a relationship of these proteins to retinal aging and possibly to retinal degeneration in RP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822152

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  51 in total

Review 1.  Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures.

Authors:  Niall Patton; Tariq Aslam; Thomas Macgillivray; Alison Pattie; Ian J Deary; Baljean Dhillon
Journal:  J Anat       Date:  2005-04       Impact factor: 2.610

2.  Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers.

Authors:  Volker Luibl; Jose M Isas; Rakez Kayed; Charles G Glabe; Ralf Langen; Jeannie Chen
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

Review 3.  Neuroprotection in glaucoma: drug-based approaches.

Authors:  William Cheung; Li Guo; M Francesca Cordeiro
Journal:  Optom Vis Sci       Date:  2008-06       Impact factor: 1.973

4.  Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma.

Authors:  T E Salt; S Nizari; M F Cordeiro; H Russ; W Danysz
Journal:  Neurotox Res       Date:  2014-08-09       Impact factor: 3.911

Review 5.  At the interface of sensory and motor dysfunctions and Alzheimer's disease.

Authors:  Mark W Albers; Grover C Gilmore; Jeffrey Kaye; Claire Murphy; Arthur Wingfield; David A Bennett; Adam L Boxer; Aron S Buchman; Karen J Cruickshanks; Davangere P Devanand; Charles J Duffy; Christine M Gall; George A Gates; Ann-Charlotte Granholm; Takao Hensch; Roee Holtzer; Bradley T Hyman; Frank R Lin; Ann C McKee; John C Morris; Ronald C Petersen; Lisa C Silbert; Robert G Struble; John Q Trojanowski; Joe Verghese; Donald A Wilson; Shunbin Xu; Li I Zhang
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

Review 6.  Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.

Authors:  T M Shah; S M Gupta; P Chatterjee; M Campbell; R N Martins
Journal:  Mol Psychiatry       Date:  2017-01-17       Impact factor: 15.992

7.  Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome.

Authors:  Sabina Janciauskiene; Torsten Krakau
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

Review 8.  The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited.

Authors:  Don H Anderson; Monte J Radeke; Natasha B Gallo; Ethan A Chapin; Patrick T Johnson; Christy R Curletti; Lisa S Hancox; Jane Hu; Jessica N Ebright; Goldis Malek; Michael A Hauser; Catherine Bowes Rickman; Dean Bok; Gregory S Hageman; Lincoln V Johnson
Journal:  Prog Retin Eye Res       Date:  2009-12-02       Impact factor: 21.198

9.  Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.

Authors:  Cheng-Ying Ho; Juan C Troncoso; David Knox; Walter Stark; Charles G Eberhart
Journal:  Brain Pathol       Date:  2013-06-28       Impact factor: 6.508

10.  Microtubule-associated protein tau in bovine retinal photoreceptor rod outer segments: comparison with brain tau.

Authors:  Akio Yamazaki; Yuji Nishizawa; Isao Matsuura; Fumio Hayashi; Jiro Usukura; Vladimir A Bondarenko
Journal:  Biochim Biophys Acta       Date:  2013-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.